EyePoint Pharmaceuticals (STU:PV3B) Common Stock : €0.05 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Common Stock?

EyePoint Pharmaceuticals's quarterly common stock increased from Jun. 2023 (€0.03 Mil) to Sep. 2023 (€0.03 Mil) and increased from Sep. 2023 (€0.03 Mil) to Dec. 2023 (€0.05 Mil).

EyePoint Pharmaceuticals's annual common stock increased from Dec. 2021 (€0.03 Mil) to Dec. 2022 (€0.03 Mil) and increased from Dec. 2022 (€0.03 Mil) to Dec. 2023 (€0.05 Mil).

EyePoint Pharmaceuticals Common Stock Historical Data

The historical data trend for EyePoint Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Common Stock Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.01

0.02

0.03

0.05

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.05

EyePoint Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines